Bleak prospects for primary progressive multiple sclerosis therapy: downs and downs, but a glimmer of hope

Ann Neurol. 2009 Oct;66(4):429-32. doi: 10.1002/ana.21880.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Murine-Derived
  • Humans
  • Multicenter Studies as Topic / methods
  • Multicenter Studies as Topic / trends
  • Multiple Sclerosis, Chronic Progressive / drug therapy*
  • Multiple Sclerosis, Chronic Progressive / epidemiology
  • Multiple Sclerosis, Chronic Progressive / physiopathology
  • Randomized Controlled Trials as Topic / methods
  • Randomized Controlled Trials as Topic / trends
  • Rituximab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab

Associated data

  • ClinicalTrials.gov/NCT00731692
  • ClinicalTrials.gov/NCT00950248